Viruses for the treatment of cellular proliferative disorders
AssigneeOncolytics Biotech Inc.
InventorsMatthew C. Coffey, Bradley G. Thompson
Life of this patent
Estimating the term…
Abstract
Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.
Claims62
A method for treating a Ras-mediated neoplasm in a mammal, comprising the steps of:
- (a) selecting a mammal with a Ras-mediated neoplasm wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to neoplastic cells of the neoplasm an effective amount of modified adenovirus lacking the gene encoding the VAI RNA under conditions which result in substantial lysis of the neoplastic cells.
A method of treating a neoplasm having an activated Ras-pathway in a human, comprising the steps of:
- (a) selecting a mammal with a Ras-mediated neoplasm wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to the neoplasm an effective amount of a modified adenovirus lacking the gene encoding the VAI RNA to result in substantial oncolysis of the neoplasm.
A method of inhibiting metastasis of a neoplasm having an activated Ras-pathway in a mammal, comprising the steps of:
- (a) selecting a mammal with a Ras-mediated neoplasm wherein the neoplasm is unable to activate a PKR response;
- and
- (b) administering to the neoplastic cells a modified adenovirus lacking the gene encoding the VAI RNA in an amount sufficient to result in substantial lysis of the neoplasm.
Dependencies are inferred from the claim text.